Jul 29, 2015

DSM Nutritional Products Ltd. and Evonik Nutrition & Care GmbH to develop algae-based omega-3 fatty acids for animal nutrition

DSM Nutritional Products Ltd. (Kaiseraugst, Switzerland) and Evonik Nutrition & Care GmbH (Essen, Germany) today announced they have entered into a joint development agreement for algae-based omega-3 fatty acid products for animal nutrition, in particular in aquaculture and pet food applications. The aim is to meet the increasing demand for omega-3 fatty acids by harnessing naturally occurring marine algae using sustainable, biotechnological processes based on natural, non-marine resources.

Under the agreement, the companies will jointly work on the development of products and explore opportunities for commercialization. The competencies that DSM and Evonik bring to the development partnership complement each other: DSM has expertise in the cultivation of marine organisms and long-established biotechnology capabilities in development and operations, whilst Evonik’s focus for decades has been on industrial amino acid biotechnology executing large-volume fermentation processes.

The envisioned algae-based omega-3 fatty acid products will be high value, natural and sustainable alternatives to fish oil, whose supply is finite. This will help the animal nutrition industry keep up with increasing demand without endangering fish stocks and will contribute to healthy and sustainable animal nutrition. Just like humans, animals also need their daily intake of essential, long-chain polyunsaturated fatty acids in their diet to ensure healthy growth. Until now, these fatty acids have been added to aquaculture feed almost exclusively from marine sources such as fish oil and fishmeal. By using algae, DSM and Evonik are looking to contribute to a more sustainable aquaculture industry.

DSM and Evonik expect that in Q4 2015 they will be able to report the first results of the algae-based omega-3 fatty acid product development.

Press Contact

press@veramaris.com

About Veramaris

Veramaris is a 50:50 joint venture of DSM and Evonik for the production of the omega-3 fatty acids EPA and DHA from natural marine algae. Located in Delft, the Netherlands, Veramaris was launched in 2018, because its parent companies shared a vision: to conserve marine life by using a resource the ocean provides – natural marine microalgae. Producing an algal oil rich in the two essential omega-3 fatty acids EPA and DHA through large-scale fermentation at its facility in Blair, Nebraska, USA, Veramaris enables partners along the value chain to become independent from wild-caught fish and meet the growing demand for animal protein responsibly.

Legal Disclaimer

This information and any recommendations, technical or otherwise, are presented in good faith and believed to be correct as of the date prepared. Recipients of this information and recommendations must make their own determination as to its suitability for their purposes. VERAMARIS EXPRESSLY DISCLAIMS ANY REPRESENTATIONS AND WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, RELIABILITY, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE (EVEN IF VERAMARIS IS AWARE OF SUCH PURPOSE) WITH RESPECT TO ANY INFORMATION AND RECOMMENDATIONS PROVIDED. IN NO EVENT SHALL VERAMARIS BE LIABLE FOR ANY DAMAGES ARISING FROM OR RELIANCE UPON, OR USE OF, ANY INFORMATION OR RECOMMENDATIONS PROVIDED HEREIN. Reference to any trade names used by other companies is neither a recommendation nor an endorsement of the corresponding product and does not imply that similar products could not be used. Veramaris reserves the right to make any changes to the information and/or recommendations at any time, without prior or subsequent notice.

Go back

Newsroom overview